Activity of anticancer agents in a three-dimensional cell culture model

Assay and Drug Development Technologies

Volumn 8, Issue 5, 2010, Pages 581-590

  Nirmalanandhan, Victor Sanjit ^a,b   Duren, Alicia ^a   Hendricks, Peter ^a   Vielhauer, George ^a,b   Sittampalam, Gurusingham Sitta ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLLAGEN GEL; DOXORUBICIN; GEMCITABINE; KU 174; KU 363; NAVELBINE; PACLITAXEL; PEMETREXED; TANESPIMYCIN; UNCLASSIFIED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MODEL; MONOLAYER CULTURE;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS;

EID: 77958613855     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0276     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bhadriraju K, Chen CS: Engineering cellular microenvironments to improve cell-based drug testing. Drug Discov Today 2002;7:612-620.
3. Yamada KM, Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-610.
4. Ivascu A, Kubbies M: Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006;11:922-932.
5. Cukierman E, Pankov R, Yamada KM: Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002;14:633-639.
6. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R: The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-285.
7. Bartholoma P, Impidjati, Reininger-Mack A, Zhang Z, Thielecke H, Robitzki A: A more aggressive breast cancer spheroid model coupled to an electronic capillary sensor system for a high-content screening of cytotoxic agents in cancer therapy: 3-dimensional in vitro tumor spheroids as a screening model. J Biomol Screen 2005;10:705-714.
8. Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W: Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen 2009;14:980-990.
9. Bartholoma P, Gorjup E, Monz D, Reininger-Mack A, Thielecke H, Robitzki A: Three-dimensional in vitro reaggregates of embryonic cardiomyocytes: a potential model system for monitoring effects of bioactive agents. J Biomol Screen 2005;10:814-822.
10. Nirmalanandhan VS, Sittampalam GS: Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. J Biomol Screen 2009;14:755-768.
11. Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
12. Hertzberg RP, Pope AJ: High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000;4:445-451.
13. Grabowski HG, Moe JL: Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention. Cancer Prev Res 2008;1:84-90.
14. Grabowski JA: DaHG: The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ 2007;28:469-479.
15. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK: Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006;8:1235-1245.
16. Walker SJ, Brugge JS: SePARating polarity and proliferation in ErbB2 oncogenesis. Nat Cell Biol 2006;8:1220-1222.
17. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ: Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998;95:14821-14826.
18. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008;452:187-193.
19. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 2006;10:625-634.
20. Khaitan D, Chandna S, Arya MB, Dwarakanath BS: Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy. J Transl Med 2006;4:12.
21. Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S: Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen 2008;13:1-8.
22. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK, Labhasetwar V: 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 2008;5:849-862.
23. Grinnell F: Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol 2003;13:264-269. (Pubitemid 36556011)
24. Montgomery D: Design and Analysis of Experiments 5th edition. John Wiley and Sons, New York, NY, 2001.
25. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007; 6:471-483.
26. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS: Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003;9:5532-5539.
27. Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'Reilly MS, Fidler IJ, Herbst RS: Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 2004;10:8613-8619.
28. Baruah H, Barry CG, Bierbach U: Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr Top Med Chem 2004;4:1537-1549.
29. Bartling B, Hofmann HS, Silber RE, Simm A: Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin. Cancer Biol Ther 2008;7:1250-1261.
30. Martelli L, Ragazzi E, Di Mario F, Basato M, Martelli M: Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency. Anticancer Res 2009;29:3931-3937.
31. Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, Cristini V: An integrated computational/experimental model of tumor invasion. Cancer Res 2006;66:1597-1604.
32. Berthod F, Germain L, Tremblay N, Auger FA: Extracellular matrix deposition by fibroblasts is necessary to promote capillary-like tube formation in vitro. J Cell Physiol 2006;207:491-498.